This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
10 - 12 June, 2025
Congress CenterBasel Switzerland

Dr. Alfredo Quijano Rubio, PhD
Chief Scientific Officer at Monod Bio
Speaker

Profile

Alfredo Quijano Rubio is a scientist and entrepreneur specializing in computational protein design. He is the co-founder and Chief Scientific Officer (CSO) of Monod Bio, a company pioneering the design of novel diagnostics and research reagents using AI-powered computational protein design. He obtained a Ph.D. in Bioengineering at the University of Washington under the mentorship of Professor David Baker, Nobel Prize in Chemistry in 2024. His research on designing conditionally-active proteins for immunotherapy and biosensors resulted in high-impact scientific publications, patents, and the creation of two companies: Neoleukin Therapeutics and Monod Bio. Alfredo has been recognized by Business Insider and by the Puget Sound Business Journal as one of the young leaders revolutionizing the healthtech sector.

Agenda Sessions

  • NovoBody Platform: Next-generation Antibodies Engineered by Computational Protein Design

    08:50